Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise (CARDIBOX) (CARDIBOX)

13 de março de 2020 atualizado por: University Hospital, Clermont-Ferrand

Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise

The high prevalence of childhood obesity is a major public health issue, worldwide. Childhood obesity is associated with a high risk of cardiovascular events in adulthood, but recent studies also point out the development of cardiovascular complications in childhood or adolescence justifying the need for early detection and appropriate therapeutic management to prevent the development of more severe abnormalities. This project proposes to evaluate the myocardial function in a fine and comprehensive way (longitudinal, circumferential and radial linear deformations, and rotation / torsion mechanics) from the deformation imaging (MRI and high-resolution echocardiography), in obese adolescents following a lifestyle intervention combining diet and physical activity.

Visão geral do estudo

Status

Desconhecido

Descrição detalhada

The investigators aim to improve knowledge of the association between epicardial adipose tissue, myocardial lipid content, and left ventricular regional myocardial function.

In this protocol, obese adolescents are recruited undergoing a 3-month lifestyle intervention residential program. Adolescents from the intervention group will be enrolled at the obesity center for the whole school year. The obesity center employs a multidisciplinary team to provide the best weight management care to adolescents during their stay. The weight loss program is an integral part of the obesity center program and fundamentally combines physical activity with a normocaloric diet monitored by a dietician. The physical activity program consists of two training sessions (aerobic and resistance training) per week. Moreover, adolescents will be engaged in two additional sessions per week, consisting in recreational activities such as ball and racquet games, trekking, snowshoeing or swimming.

There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.

Statistical analysis will be performed using Stata software (version 13; Stata-Corp, College Station, Tex., USA). All statistical tests will be two-sided and p inferior to 0.05 will be considered significant. Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of numbers, mean standard deviation or median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results. The main analysis will be performed with the Stata software (version 13, StataCorp, College Station). All statistical tests will be carried out at a risk of error of first species α set at 5%. Most of the analysis of the secondary evaluation criteria will be exploratory in nature and may lack power in terms of numbers. As discussed by Feise in 2002,104 the adjustment of the risk of error of 1st species will not be systematically proposed, but case by case in view of clinical considerations and not only statistical (e.g. Sidak correction for the analysis of correlation coefficients).

Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of standard deviation or mean median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results.

Intergroup comparisons will be systematically conducted without adjustment and by adjusting for factors whose distribution could be unbalanced between groups. Patients will be described and compared between groups at inclusion according to the following variables: compliance with eligibility criteria, epidemiological characteristics, clinical characteristics and characteristics of possible treatments. The baseline comparability of the two groups will be assessed on the main characteristics of the participants and potential factors associated with the primary outcome. A possible difference between the two groups on one of these characteristics will be determined according to clinical considerations and not solely statistical ones.

Tipo de estudo

Intervencional

Inscrição (Antecipado)

50

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Clermont-Ferrand, França, 63000
        • CHU de Clermont-Ferrand

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

12 anos a 16 anos (Filho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • age between 12 and 16 years old
  • mature (menarche)
  • suitable for physical activity
  • able to give an informative consent
  • affiliated at French insurance company
  • consent from the legal representatives
  • For obese adolescents: BMI greater than the 97th percentile of national curves.
  • For the control group: to be normal-weighted (no obesity if overweight, <85th percentile of national curves).

Exclusion Criteria:

  • Medical or surgical history judged by the investigator as incompatible with the study
  • Drugs that may interfere with the study results
  • Cardiovascular, hepatic, psychiatric, renal, or endocrinological diseases
  • Smoking
  • Alcohol consumption
  • Intense physical activity in competition

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Prevenção
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Obese adolescents
BMI greater than the 97th percentile of national curves. Participants will follow a 3-month lifestyle intervention

Adolescents from the intervention group will be enrolled at the obesity center for the whole school year (i.e., 10 months). The physical activity program consists of two training sessions (aerobic and resistance training) per week.

There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.

Sem intervenção: Control group
to be normal-weighted (no obesity if overweight, <85th percentile of national curves).

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
cardiac ectopic fat deposits
Prazo: Month 3
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
Month 3
cardiac ectopic fat deposits
Prazo: Day 0
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
Day 0
cardiac ectopic fat deposits
Prazo: Day 0
Quantification of cardiac ectopic fat deposits (volume using MRI)
Day 0
cardiac ectopic fat deposits
Prazo: Month 3
Quantification of cardiac ectopic fat deposits (volume using MRI)
Month 3
cardiac ectopic fat deposits
Prazo: Month 3
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
Month 3
cardiac ectopic fat deposits
Prazo: Day 0
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
Day 0
left myocardial regional function
Prazo: Month 3
left myocardial regional function (echocardiography)
Month 3
left myocardial regional function
Prazo: Month 3
left myocardial regional function (MRI)
Month 3
left myocardial regional function
Prazo: Day 0
left myocardial regional function (echocardiography)
Day 0
left myocardial regional function
Prazo: Day 0
left myocardial regional function (MRI)
Day 0

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
macrovascularisation
Prazo: Day 0
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
Day 0
macrovascularisation
Prazo: Month 3
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
Month 3
microvascularisation
Prazo: Month 3
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
Month 3
microvascularisation
Prazo: Day 0
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
Day 0
microvascularisation
Prazo: Day 0
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
Day 0
microvascularisation
Prazo: Month 3
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
Month 3
microvascularisation
Prazo: Month 3
measure of microvascular perfusion using Iontophoresis procedure
Month 3
microvascularisation
Prazo: Day 0
measure of microvascular perfusion using Iontophoresis procedure
Day 0
microvascularisation
Prazo: Day 0
measure of microvascular perfusion using flowmotion
Day 0
microvascularisation
Prazo: Month 3
measure of microvascular perfusion using flowmotion
Month 3
heart rate variability
Prazo: Month 3
measure of heart rate variability using a holter
Month 3
heart rate variability
Prazo: Day 0
measure of heart rate variability using a holter
Day 0
skin conductance
Prazo: Day 0
measure of skin conductance using Wristband electrodes - Empatica E4
Day 0
skin conductance
Prazo: Month 3
measure of skin conductance using Wristband electrodes - Empatica E4
Month 3
Liver steatosis
Prazo: Month 3
measure of liver steatosis by MRI
Month 3
Liver steatosis
Prazo: Day 0
measure of liver steatosis by MRI
Day 0
Liver steatosis
Prazo: Day 0
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
Day 0
Liver steatosis
Prazo: Month 3
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
Month 3
Liver steatosis
Prazo: month 3
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
month 3
Liver steatosis
Prazo: Day 0
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
Day 0
Liver fibrosis
Prazo: Day 0
measure of liver fibrosis by fibroscanner (liver stiffness)
Day 0
Liver fibrosis
Prazo: Month 3
measure of liver fibrosis by fibroscanner (liver stiffness)
Month 3
Liver fibrosis
Prazo: Month 3
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
Month 3
Liver fibrosis
Prazo: Day 0
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
Day 0
blood pressure
Prazo: Day0
measure of blood pressure using sphygmomanometer
Day0
blood pressure
Prazo: month 3
measure of blood pressure using sphygmomanometer
month 3
Fitness
Prazo: Month 3
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
Month 3
Fitness
Prazo: Day 0
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
Day 0
muscle mass
Prazo: Month 3
measure of muscle mass using impedancemeter
Month 3
fat mass
Prazo: Month 3
measure of muscle mass using impedancemeter
Month 3
bone structure
Prazo: Month 3
measure of muscle mass using impedancemeter
Month 3
muscle mass
Prazo: Day 0
measure of muscle mass using impedancemeter
Day 0
fat mass
Prazo: Day 0
measure of muscle mass using impedancemeter
Day 0
bone structure
Prazo: Day 0
measure of muscle mass using impedancemeter
Day 0
muscle mass
Prazo: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
fat mass
Prazo: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
bone structure
Prazo: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
muscle mass
Prazo: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
fat mass
Prazo: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
bone structure
Prazo: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
muscle mass
Prazo: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
fat mass
Prazo: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
bone structure
Prazo: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
muscle mass
Prazo: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
fat mass
Prazo: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
bone structure
Prazo: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
muscle mass
Prazo: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
fat mass
Prazo: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
bone structure
Prazo: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
muscle mass
Prazo: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
fat mass
Prazo: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
bone structure
Prazo: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
depression
Prazo: Day 0
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
Day 0
depression
Prazo: Month 3
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
Month 3
anxiety
Prazo: Day 0
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always". It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
Day 0
anxiety
Prazo: Month 3
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always". It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
Month 3
General health
Prazo: Day 0
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
Day 0
General health
Prazo: Month 3
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
Month 3
Stress
Prazo: day 0
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
day 0
Stress
Prazo: Month 3
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Month 3
Fatigue
Prazo: Day 0
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Day 0
Fatigue
Prazo: Month 3
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Month 3
Sleep
Prazo: day 0
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
day 0
Sleep
Prazo: Month 3
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
Month 3
Burnout
Prazo: day 0
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
day 0
Burnout
Prazo: Month 3
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
Month 3
Mindfulness
Prazo: Day 0
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
Day 0
Mindfulness
Prazo: Month 3
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
Month 3
Coping
Prazo: Day 0
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
Day 0
Coping
Prazo: Month 3
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
Month 3
Emotions
Prazo: Day 0
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
Day 0
Emotions
Prazo: Month 3
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
Month 3
Perception of work
Prazo: Day 0
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree). It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
Day 0
Perception of work
Prazo: Month 3
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree). It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
Month 3
Self-efficacy
Prazo: Day 0
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
Day 0
Self-efficacy
Prazo: Month 3
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
Month 3
Alexithymia
Prazo: Day 0
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
Day 0
Alexithymia
Prazo: Month 3
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
Month 3
Illness perception
Prazo: Day 0
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
Day 0
Illness perception
Prazo: Month 3
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
Month 3
Metacognition
Prazo: Day 0
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
Day 0
Metacognition
Prazo: Month 3
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
Month 3
Time perception
Prazo: Day 0
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale. It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
Day 0
Time perception
Prazo: Month 3
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale. It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
Month 3
Physical activity
Prazo: Day 0
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
Day 0
Physical activity
Prazo: Month 3
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
Month 3
Life style
Prazo: Day 0
life style is assessed with a questionnaire on coffee consumption, food intake, etc
Day 0
Life style
Prazo: Month 3
life style is assessed with a questionnaire on coffee consumption, food intake, etc
Month 3
cholesterol
Prazo: Day 0
measure by blood analyses to evaluate alloplastic load
Day 0
triglycerides
Prazo: Day 0
measure by blood analyses to evaluate alloplastic load
Day 0
cholesterol
Prazo: Month 3
measure by blood analyses to evaluate alloplastic load
Month 3
triglycerides
Prazo: Month 3
measure by blood analyses to evaluate alloplastic load
Month 3
Cortisol
Prazo: Day 0
hormone measure by blood analyses to evaluate alloplastic load
Day 0
Cortisol
Prazo: Month 3
hormone measure by blood analyses to evaluate alloplastic load
Month 3
DHEAS
Prazo: day 0
hormone measure by blood analyses to evaluate alloplastic load
day 0
DHEAS
Prazo: Month 3
hormone measure by blood analyses to evaluate alloplastic load
Month 3
BDNF
Prazo: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
BDNF
Prazo: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
CRP
Prazo: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
pro-inflammatory cytokines
Prazo: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
TNF alpha
Prazo: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
CRP
Prazo: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
pro-inflammatory cytokines
Prazo: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
TNF alpha
Prazo: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
NPY
Prazo: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
NPY
Prazo: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
Leptin
Prazo: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Leptin
Prazo: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
Ghrelin
Prazo: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Ghrelin
Prazo: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
NPY
Prazo: day 0
measure by blood analyses to evaluate appetite regulation
day 0
NPY
Prazo: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
adiponectine
Prazo: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
adiponectine
Prazo: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
CCK
Prazo: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Month 3
Prazo: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Insulin
Prazo: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
Insulin
Prazo: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
HbA1c
Prazo: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
HbA1c
Prazo: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
glucose
Prazo: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
glucose
Prazo: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
Albumin
Prazo: Day 0
measure by blood analyses to evaluate protid metabolism
Day 0
Albumin
Prazo: Month 3
measure by blood analyses to evaluate protid metabolism
Month 3
transthyretin
Prazo: Day 0
measure by blood analyses to evaluate protid metabolism
Day 0
transthyretin
Prazo: Month 3
measure by blood analyses to evaluate protid metabolism
Month 3
Homeostasis
Prazo: Day 0
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
Day 0
Homeostasis
Prazo: Month 3
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
Month 3
Osteoresorption
Prazo: Day 0
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
Day 0
Osteoresorption
Prazo: Month 3
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
Month 3
Osteoformation
Prazo: Day 0
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
Day 0
Osteoformation
Prazo: Month 3
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
Month 3
VEGF
Prazo: Day 0
measure by blood analyses to evaluate cardiovascular function
Day 0
VEGF
Prazo: Month 3
measure by blood analyses to evaluate cardiovascular function
Month 3
PAI1
Prazo: Day 0
measure by blood analyses to evaluate cardiovascular function
Day 0
PAI1
Prazo: Month 3
measure by blood analyses to evaluate cardiovascular function
Month 3
weight
Prazo: Day 0
measure of weight in kilograms
Day 0
weight
Prazo: Month 3
measure of weight in kilograms
Month 3
waist circumference
Prazo: Day 0
measure of waist circumference in centimetres
Day 0
waist circumference
Prazo: Month 3
measure of waist circumference in centimetres
Month 3

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Antecipado)

1 de setembro de 2020

Conclusão Primária (Antecipado)

1 de junho de 2021

Conclusão do estudo (Antecipado)

1 de junho de 2021

Datas de inscrição no estudo

Enviado pela primeira vez

10 de fevereiro de 2020

Enviado pela primeira vez que atendeu aos critérios de CQ

13 de março de 2020

Primeira postagem (Real)

17 de março de 2020

Atualizações de registro de estudo

Última Atualização Postada (Real)

17 de março de 2020

Última atualização enviada que atendeu aos critérios de controle de qualidade

13 de março de 2020

Última verificação

1 de fevereiro de 2020

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • RBHP 2019 DUTHEIL
  • 2019-A01804-53 (Outro identificador: ANSM)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

Indeciso

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

3
Se inscrever